Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

Online
ISSN
1437-4331
See all formats and pricing
Volume 44, Issue 8 (Aug 2006)

Issues

Association of aminothiols with the clinical outcome in hemodialysis patients: comparison of chromatography and immunoassay for homocysteine determination

Stéphanie Badiou
  • Biochemistry Laboratory, Lapeyronie University Hospital, Montpellier, France
/ Nathalie Terrier
  • Biochemistry Laboratory, Lapeyronie University Hospital, Montpellier, France
/ Isabelle Jaussent
  • French National Institute of Health and Medical Research, Inserm E 0361, Montpellier, France
/ Estelle Naudin
  • Biochemistry Laboratory, Lapeyronie University Hospital, Montpellier, France
/ François Maurice
  • Hemodialysis Center Languedoc Mediterranee, Montpellier, France
/ Anne-Marie Dupuy
  • Biochemistry Laboratory, Lapeyronie University Hospital, Montpellier, France
/ Hélène Leray-Moragues
  • Department of Nephrology, Lapeyronie University Hospital, Montpellier, France
/ Jean-Pierre Rivory
  • Hemodialysis Center Languedoc Mediterranee, Montpellier, France
/ Cécile Delcourt
  • French National Institute of Health and Medical Research, Inserm U593, Bordeaux, France and Université Victor Segalen Bordeaux 2, Bordeaux, France
/ Bernard Canaud
  • Department of Nephrology, Lapeyronie University Hospital, Montpellier, France
/ Jean-Paul Cristol
  • Biochemistry Laboratory, Lapeyronie University Hospital, Montpellier, France
Published Online: 2011-09-21 | DOI: https://doi.org/10.1515/CCLM.2006.184

Abstract

Background: Controversial results on hyperhomocysteinemia and cardiovascular risk in hemodialysis (HD) could be due in part to the methodology used for homocysteine (Hcy) determination.

Objective: The aim of this study was to compare the influence of the method used for Hcy determination (chromatography or immunoassay) with regard to the association of Hcy with cardiovascular mortality rate in HD patients in a 3-year prospective study.

Methods: A total of 162 patients undergoing HD were included in a cohort study. Baseline Hcy levels were measured by HPLC and fluorescence polarization immunoassay (FPIA). Cysteine and cysteinylglycine were determined simultaneously with Hcy measurement by HPLC.

Results: Hcy levels obtained with both methods were highly correlated (r2=0.927, p<0.0001). An increased relative risk (RR) for cardiovascular mortality (n=31) was found between the highest against lowest tertile of Hcy for both HPLC (RR 2.74, 95% CI 1.07–7.02; p<0.05) and FPIA (RR 2.76, 95% CI 0.99–7.70; p=0.05). Interestingly, increased cysteine (≥452 μmol/L) and cysteinylglycine (≥36.6μmol/L) levels were associated with a decreased RR of non-cardiovascular death (n=26) (RR 0.27, 95% CI 0.09–0.79; p=0.02) for cysteine and (RR 0.28, 95% CI 0.09–0.90; p=0.03) for cysteinylglycine when compared to the first tertile.

Conclusions: This study demonstrated an increased risk of cardiovascular mortality in HD patients with Hcy values in the third tertile, independent of the method used. HPLC offers the advantage of simultaneous determination of other aminothiols that appear to be associated with non-cardiovascular mortality.

Clin Chem Lab Med 2006;44:949–54.

Keywords: aminothiols; cardiovascular; chromatography; hemodialysis; homocysteine; immunoassay

References

  • 1.

    Van Guldener C, Robinson K. Homocysteine and renal disease. Semin Thromb Hemost 2000; 26:313–24. [Crossref]

  • 2.

    Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61:609–14. [Crossref]

  • 3.

    Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 2004; 17:405–10.

  • 4.

    Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 2005; 6:27–36. [Crossref]

  • 5.

    Chen Z, Li CS, Zhang J, Pang BS, Xia CQ, Liu XF. Relationship between endothelial dysfunction and serum homocysteine in patients with coronary lesions. Chin Med Sci J 2005; 20:63–6.

  • 6.

    Southern FN, Cruz N, Fink LM, Cooney CA, Barone GW, Eidt JF, et al. Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg 1998; 28:909–18. [Crossref]

  • 7.

    Bowden RG, Wyatt FB, Wilson R, Wilborn C, Gentile M. Homocysteine and vascular access thrombosis in a cohort of end-stage renal disease patients. Ren Fail 2004; 26:709–14. [Crossref]

  • 8.

    Leskinen Y, Lehtimaki T, Loimaala A, Huhtala H, Salenius JP, Oja SS, et al. Homocysteine and carotid atherosclerosis in chronic renal failure – the confounding effect of renal function. Atherosclerosis 2004; 175:315–23. [Crossref]

  • 9.

    Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15:442–53. [Crossref]

  • 10.

    Ducros V, Demuth K, Sauvant MP, Quillard M, Causse E, Candito M, et al., SFBC working group on homocysteine. French Society for Clinical Biology. Methods for homocysteine analysis and biological relevance of the results. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 781:207–26. [Crossref]

  • 11.

    Lonati S, Novembrino C, Ippolito S, Accinni R, Galli C, Troonen H, et al. Analytical performance and method comparison study of the total homocysteine fluorescence polarization immunoassay (FPIA) on the AxSYM analyzer. Clin Chem Lab Med 2004; 42:228–34. [Crossref]

  • 12.

    Brunelli T, Pepe G, Marcucci R, Giusti B, Prisco D, Abbate R, et al. Comparison of three methods for total homocysteine plasma determination. Clin Lab 2001; 47:393–7.

  • 13.

    Blanco-Vaca F, Arcelus R, Gonzalez-Sastre F, Ordonez-Llanos J, Queralto-Compano JM. Comparison of the Abbott IMx and a high-performance liquid chromatography method for measuring total plasma homocysteine. Clin Chem Lab Med 2000; 38:327–9.

  • 14.

    Barbe F, Abdelmouttaleb I, Chango A, Gerard P, Quilliot D, Klein M, et al. Detection of moderate hyperhomocysteinemia: comparison of the Abbott fluorescence polarization immunoassay with the Bio-Rad and SBD-F high-performance liquid chromatographic assays. Amino Acids 2001; 20:435–40. [Crossref]

  • 15.

    Hanson NQ, Eckfeldt JH, Schwichtenberg K, Aras O, Tsai MY. Interlaboratory variation of plasma total homocysteine measurements: results of three successive homocysteine proficiency testing surveys. Clin Chem 2002; 48:1539–45.

  • 16.

    Garred LJ, Barichello DL, DiGiuseppe B, McCready WG, Canaud B. Simple Kt/V formulas based on urea mass balance theory. ASAIO J 1994; 40:997–1004. [Crossref]

  • 17.

    Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8:135–60. [Crossref]

  • 18.

    Sigit JI, Hages M, Brensing KA, Frotscher U, Pietrzik K, von Bergmann K, et al. Total plasma homocysteine and related amino acids in end-stage renal disease (ESRD) patients measured by gas chromatography-mass spectrometry – comparison with the Abbott IMx homocysteine assay and the HPLC method. Clin Chem Lab Med 2001; 39:681–90. [Crossref]

  • 19.

    Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6:121–5.

  • 20.

    Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94:2743–8. [Crossref]

  • 21.

    Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97:138–41. [Crossref]

  • 22.

    Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106:100–5. [Crossref]

  • 23.

    Fellah H, Feki M, Hsairi M, Sanhaji H, Kaabachi N, Ben Abdallah T, et al. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients. Clin Chem Lab Med 2003; 41:675–80. [Crossref]

  • 24.

    Brzosko S, Lebkowska U, Malyszko J, Hryszko T, Krauze-Brzosko K, Mysliwiec M. Intima media thickness of common carotid arteries is associated with traditional risk factors and presence of ischaemic heart disease in hemodialysis patients. Physiol Res 2005; 54:497–504.

  • 25.

    Suliman ME, Stenvinkel P, Qureshi AR, Barany P, Heimburger O, Anderstam B, et al. Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. Am J Kidney Dis 2004; 44:455–65. [Crossref]

  • 26.

    Gonella M, Calabrese G, Mengozzi A, Aleo AG, Vagelli G, Mazzotta A, et al. The achievement of normal homocysteinemia in regular extracorporeal dialysis patients. J Nephrol 2004; 17:411–3.

  • 27.

    Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69:2087–93. [Crossref]

  • 28.

    Suliman ME, Barany P, Divino Filho JC, Qureshi AR, Stenvinkel P, Heimburger O, et al. Influence of nutritional status on plasma and erythrocyte sulphur amino acids, sulph-hydryls, and inorganic sulphate in end-stage renal disease. Nephrol Dial Transplant 2002; 17:1050–6. [Crossref]

About the article

Corresponding author: Professor Jean-Paul Cristol, Biochemistry Laboratory, Lapeyronie University Hospital, 371 Avenue Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France Phone: +33-467-338314, Fax: +33-467-338393,


Received: 2006-03-23

Accepted: 2006-05-23

Published Online: 2011-09-21

Published in Print: 2006-08-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2006.184. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Stéphanie BADIOU, Marion MORENA, Anne-Sophie BARGNOUX, Isabelle JAUSSENT, Annie RODRIGUEZ, Helene LERAY-MORAGUES, Lofti CHALABI, Jean-Yves BOSC, Bernard CANAUD, and Jean-Paul CRISTOL
Hemodialysis International, 2011, Volume 15, Number 4, Page 515

Comments (0)

Please log in or register to comment.
Log in